The Role of Photodynamic Therapy in the Esophagus

Gastrointestinal Endoscopy Clinics of North America

Volumn 20, Issue 1, 2010, Pages 35-53

  Gross, Seth A ^a   Wolfsen, Herbert C ^b,c  

^a NORWALK HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

^c Mayo Clinic   (United States)

Author keywords

Aminolevulinic acid; HPPH (Photochlor); mTHPC (Foscan); Porfimer sodium; Subsquamous Barrett glands

Indexed keywords

2 (1 HEXYLOXYETHYL) 2 DEVINYL PYROPHEOPHORBIDE A; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; BENZOPORPHYRIN DERIVATIVE; BIOLOGICAL MARKER; CHLOROALUMINUM PHTHALOCYANINE; LEMUTEPORFIN; LU TEX; LUTETIUM TEXAPHYRIN; OMEPRAZOLE; PHEOPHORBIDE; PHOTOCHLOR; PHOTOFRIN; PHOTOSAN; PHTHALOCYANINE ALUMINUM; PREDNISONE; PURPURIN; TALAPORFIN; TEMOPORFIN; UNCLASSIFIED DRUG; VERTEPORFIN;

ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; CLINICAL TRIAL; DOSIMETRY; DRUG FATALITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL DYSPLASIA; ESOPHAGUS CARCINOMA; ESOPHAGUS DISEASE; ESOPHAGUS RESECTION; ESOPHAGUS STRICTURE; HUMAN; NEUROPATHY; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PORPHYRIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THORAX PAIN; TREATMENT RESPONSE;

ADENOCARCINOMA; AMINOLEVULINIC ACID; BARRETT ESOPHAGUS; DIHEMATOPORPHYRIN ETHER; ESOPHAGEAL NEOPLASMS; HUMANS; MESOPORPHYRINS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 70749144311     PISSN: 10525157     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.giec.2009.07.008     Document Type: Review

References (108)

1. Dougherty T.J., Kaufman J.E., Goldfarb A., et al. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 38 8 (1978) 2628-2635
2. Macdonald J., and Dougherty T. Basic principles of photodynamic therapy. J Porphyrins Phthalocyanines 5 2 (2001) 105-129
3. McCaughan Jr. J.S., Ellison E.C., Guy J.T., et al. Photodynamic therapy for esophageal malignancy: a prospective twelve-year study. Ann Thorac Surg 62 4 (1996) 1005-1009
4. Litle V.R., Luketich J.D., Christie N.A., et al. Photodynamic therapy as palliation for esophageal cancer: experience in 215 patients. Ann Thorac Surg 76 5 (2003) 1687-1692 [discussion: 92-3]
5. Lightdale C.J., Heier S.K., Marcon N.E., et al. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 42 6 (1995) 507-512
6. Overholt B.F., Lightdale C.J., Wang K.K., et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 62 4 (2005) 488-498
7. Overholt B.F., Wang K.K., Burdick J.S., et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 66 (2007) 460-468
8. Wolfsen H.C. Endoluminal therapy for Barrett's esophagus [abstract]. Gastrointest Endosc Clin N Am 17 1 (2007) 59-82
9. Wolfsen H.C. Present status of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. J Clin Gastroenterol 39 3 (2005) 189-202
10. Wolfsen H.C. Carpe luz-seize the light: endoprevention of esophageal adenocarcinoma when using photodynamic therapy with porfimer sodium. Gastrointest Endosc 62 4 (2005) 499-503
11. Wolfsen H.C. Endoprevention of esophageal cancer: endoscopic ablation of Barrett's metaplasia and dysplasia. Expert Rev Med Devices 2 6 (2005) 713-723
12. Prosst R.L., Wolfsen H.C., and Gahlen J. Photodynamic therapy for esophageal diseases: a clinical update. Endoscopy 35 12 (2003) 1059-1068
13. Wang K.K. Current status of photodynamic therapy of Barrett's esophagus. Gastrointest Endosc 49 3 Pt 2 (1999) S20-S23
14. Overholt B.F., Panjehpour M., and Halberg D.L. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 58 2 (2003) 183-188
15. Sampliner R.E. Prevention of adenocarcinoma by reversing Barrett's esophagus with mucosal ablation. World J Surg 27 9 (2003) 1026-1029
16. Falk G.W. Barrett's esophagus. Gastroenterology 122 6 (2002) 1569-1591
17. Cameron A.J., Zinsmeister A.R., Ballard D.J., et al. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 99 4 (1990) 918-922
18. Cameron A.J., Ott B.J., and Payne W.S. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 313 14 (1985) 857-859
19. Reid B.J. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 20 4 (1991) 817-834
20. Ward E.M., Wolfsen H.C., Achem S.R., et al. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol 101 1 (2006) 12-17
21. Conio M., Lapertosa G., Blanchi S., et al. Barrett's esophagus: an update. Crit Rev Oncol Hematol 46 2 (2003) 187-206
22. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 10 (1998) 2049-2053
23. Montgomery E., Bronner M.P., Goldblum J.R., et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 32 4 (2001) 368-378
24. Buttar N.S., Wang K.K., Lutzke L.S., et al. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc 54 6 (2001) 682-688
25. Schnell T.G., Sontag S.J., Chejfec G., et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 120 7 (2001) 1607-1619
26. Reid B.J., Levine D.S., Longton G., et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95 7 (2000) 1669-1676
27. Weston A.P., and Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma. Am J Gastroenterol 97 12 (2002) 2998-3006
28. Hameeteman W., Tytgat G.N., Houthoff H.J., et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 96 5 Pt 1 (1989) 1249-1256
29. Zaninotto G., Minnei F., Guirroli E., et al. The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results. Dig Liver Dis 39 1 (2007) 18-25
30. Tokar J.L., Haluszka O., and Weinberg D.S. Endoscopic therapy of dysplasia and early-stage cancers of the esophagus. Semin Radiat Oncol 17 1 (2007) 10-21
31. Dougherty T.J. An update on photodynamic therapy applications. J Clin Laser Med Surg 20 1 (2002) 3-7
32. Dougherty T.J., Gomer C.J., Henderson B.W., et al. Photodynamic therapy. J Natl Cancer Inst 90 12 (1998) 889-905
33. Ackroyd R., Kelty C., Brown N., et al. The history of photodetection and photodynamic therapy. Photochem Photobiol 74 5 (2001) 656-669
34. Bown S.G., and Rogowska A.Z. New photosensitizers for photodynamic therapy in gastroenterology. Can J Gastroenterol 13 5 (1999) 389-392
35. Bellnier D.A., Greco W.R., Nava H., et al. Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy. Cancer Chemother Pharmacol 57 1 (2006) 40-45
36. Overholt B., Panjehpour M., Tefftellar E., et al. Photodynamic therapy for treatment of early adenocarcinoma in Barrett's esophagus. Gastrointest Endosc 39 1 (1993) 73-76
37. Overholt B.F., Panjehpour M., and Haydek J.M. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 49 1 (1999) 1-7
38. Wang K.K., and Kim J.Y. Photodynamic therapy in Barrett's esophagus. Gastrointest Endosc Clin N Am 13 3 (2003) 483-489 vii
39. Wolfsen H.C., Woodward T.A., and Raimondo M. Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma. Mayo Clin Proc 77 11 (2002) 1176-1181
40. Wolfsen H.C., Hemminger L.L., Wallace M.B., et al. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Ther 20 10 (2004) 1125-1131
41. Wang K.K., Wong Kee Song L.M., Buttar N.S., et al. Barrett's esophagus after photodynamic therapy: risk of cancer development during long term follow up. [abstract]. Gastroenterology 126 Suppl 2 (2004) A50
42. Wolfsen H.C., and Hemminger L.L. Photodynamic therapy for dysplastic Barrett's esophagus and mucosal adenocarcinoma. [abstract]. Gastrointest Endosc 59 5 (2004) AB251
43. Ukleja A., Scolapio J.S., and Wolfsen H.C. Nutritional consequences following photodynamic therapy. Gastrotenterology 116 4 Part 2 (1999) A582
44. Nijhawan P.K., and Wang K.K. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointest Endosc 52 3 (2000) 328-332
45. Panjehpour M., Overholt B.F., Haydek J.M., et al. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol 95 9 (2000) 2177-2184
46. Pacifico R.J., Wang K.K., Wong Kee Song L.M., et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 1 4 (2003) 252-257
47. Prasad G.A., Wang K.K., Buttar N.S., et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 132 4 (2007) 1226-1233
48. Foroulis C.N., and Thorpe J.A. Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer. Eur J Cardiothorac Surg 29 1 (2006) 30-34
49. Keeley S.B., Pennathur A., Gooding W., et al. Photodynamic therapy with curative intent for Barrett's esophagus with high grade dysplasia and superficial esophageal cancer. Ann Surg Oncol 14 8 (2007) 2406-2410
50. Hemminger L.L., and Wolfsen H.C. Photodynamic therapy for Barrett's esophagus and high grade dysplasia: results of a patient satisfaction survey. Gastroenterol Nurs 25 4 (2002) 139-141
51. Hur C., Nishioka N.S., and Gazelle G.S. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig Dis Sci 48 7 (2003) 1273-1283
52. Wolfsen H.C., Hemminger L.L., and DeVault K.R. Barrett's dysplasia and mucosal carcinoma patients referred for photodynamic therapy - do they come from surveillance programs?. [abstract]. Gastrointest Endosc 59 5 (2004) AB265
53. Bronner M.P., Overholt B.F., Taylor S.L., et al. Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia. Gastroenterology 136 1 (2009) 56-64 quiz 351-352
54. Yachimski P., Puricelli W.P., and Nishioka N.S. Patient predictors of esophageal stricture development after photodynamic therapy. Clin Gastroenterol Hepatol 6 3 (2008) 302-308
55. Andrejevic-Blant S., Hadjur C., Ballini J.P., et al. Photodynamic therapy of early squamous cell carcinoma with tetra(m-hydroxyphenyl)chlorin: optimal drug-light interval. Br J Cancer 76 8 (1997) 1021-1028
56. Andrejevic-Blant S., Grosjean P., Ballini J.P., et al. Localization of tetra(m-hydroxyphenyl)chlorin (Foscan) in human healthy tissues and squamous cell carcinomas of the upper aero-digestive tract, the esophagus and the bronchi: a fluorescence microscopy study. J Photochem Photobiol B 61 1-2 (2001) 1-9
57. Gossner L., May A., Sroka R., et al. A new long-range through-the-scope balloon applicator for photodynamic therapy in the esophagus and cardia. Endoscopy 31 5 (1999) 370-376
58. Gossner L., May A., Sroka R., et al. Photodynamic destruction of high grade dysplasia and early carcinoma of the esophagus after the oral administration of 5-aminolevulinic acid. Cancer 86 10 (1999) 1921-1928
59. Gossner L., Stolte M., Sroka R., et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 114 3 (1998) 448-455
60. Javaid B., Watt P., and Krasner N. Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-tetrahydroxyphenyl chlorin): a preliminary study. Lasers Med Sci 17 1 (2002) 51-56
61. Etienne J., Dorme N., Bourg-Heckly G., et al. Photodynamic therapy with green light and m-tetrahydroxyphenyl chlorin for intramucosal adenocarcinoma and high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc 59 7 (2004) 880-889
62. Lovat L.B., Jamieson N.F., Novelli M.R., et al. Photodynamic therapy with m-tetrahydroxyphenyl chlorin for high-grade dysplasia and early cancer in Barrett's columnar lined esophagus. Gastrointest Endosc 62 4 (2005) 617-623
63. Bedwell J., MacRobert A.J., Phillips D., et al. Fluorescence distribution and photodynamic effect of ALA-induced PP IX in the DMH rat colonic tumour model. Br J Cancer 65 6 (1992) 818-824
64. Kennedy J.C., and Pottier R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 14 4 (1992) 275-292
65. Peng Q., Berg K., Moan J., et al. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol 65 2 (1997) 235-251
66. Webber J., Kessel D., and Fromm D. Side effects and photosensitization of human tissues after aminolevulinic acid. J Surg Res 68 1 (1997) 31-37
67. Ackroyd R., Brown N.J., Davis M.F., et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut 47 5 (2000) 612-617
68. Ackroyd R., Brown N.J., Davis M.F., et al. Aminolevulinic acid-induced photodynamic therapy: safe and effective ablation of dysplasia in Barrett's esophagus. Dis Esophagus 13 1 (2000) 18-22
69. Barr H., Shepherd N.A., Dix A., et al. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 348 9027 (1996) 584-585
70. Orth K., Stanescu A., Ruck A., et al. [Photodynamic ablation and argon-plasma coagulation of premalignant and early-stage malignant lesions of the oesophagus-an alternative to surgery?]. Chirurg 70 4 (1999) 431-438 [in German]
71. Pech O., Gossner L., May A., et al. Long term results of PDT for early neoplasia in Barrett's esophagus. Gastrointest Endosc 62 1 (2005) 24-30
72. Guelrud M., Herrera I., Essenfeld H., et al. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 53 6 (2001) 559-565
73. Behrens A., May A., Gossner L., et al. Curative treatment for high-grade intraepithelial neoplasia in Barrett's esophagus. Endoscopy 37 10 (2005) 999-1005
74. May A., Gossner L., Pech O., et al. Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques. Endoscopy 34 8 (2002) 604-610
75. Sylantiev C., Schoenfeld N., Mamet R., et al. Acute neuropathy mimicking porphyria induced by aminolevulinic acid during photodynamic therapy. Muscle Nerve 31 3 (2005) 390-393
76. Siersema P.D. Photodynamic therapy for Barrett's esophagus: not yet ready for the premier league of endoscopic interventions. Gastrointest Endosc 62 4 (2005) 503-507
77. Ortner M.A., Zumbusch K., Liebetruth J., et al. Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett's esophagus? A pilot study. Endoscopy 34 8 (2002) 611-616
78. Ragunath K., Krasner N., Raman V.S., et al. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol 40 7 (2005) 750-758
79. Kelty C.J., Ackroyd R., Brown N.J., et al. Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus. Surg Endosc 18 3 (2004) 452-458
80. Kelty C.J., Ackroyd R., Brown N.J., et al. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 20 11-12 (2004) 1289-1296
81. Hage M., Siersema P.D., van Dekken H., et al. 5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut 53 6 (2004) 785-790
82. Peters F., Kara M., Rosmolen W., et al. Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in Barrett esophagus after endoscopic resection. Endoscopy 37 5 (2005) 418-424
83. Mackenzie G., Selvasekar C., Jamieson N., et al. Low incidence of esophageal adenocarcinoma following optimal regimen of ALA PDT for high grade dysplasia in Barrett's esophagus. [abstract]. Gastrointest Endosc 65 5 (2007) AB132
84. Boere I.A., Robinson D.J., de Bruijn H.S., et al. Monitoring in situ dosimetry and protoporphyrin IX fluorescence photobleaching in the normal rat esophagus during 5-aminolevulinic acid photodynamic therapy. Photochem Photobiol 78 3 (2003) 271-277
85. Cheung R., Solonenko M., Busch T.M., et al. Correlation of in vivo photosensitizer fluorescence and photodynamic-therapy-induced depth of necrosis in a murine tumor model. J Biomed Opt 8 2 (2003) 248-252
86. Radu A., Conde R., Fontolliet C., et al. Mucosal ablation with photodynamic therapy in the esophagus: optimization of light dosimetry in the sheep model. Gastrointest Endosc 57 7 (2003) 897-905
87. Panjehpour M., Overholt B.F., Phan M.N., et al. Optimization of light dosimetry for photodynamic therapy of Barrett's esophagus: efficacy vs. incidence of stricture after treatment. Gastrointest Endosc 61 1 (2005) 13-18
88. Gill K.R., Wolfsen H.C., Preyer N.W., et al. Pilot study on light dosimetry variables for photodynamic therapy of Barrett's esophagus with high-grade dysplasia. Clin Cancer Res 15 5 (2009) 1830-1836
89. van den Bergh H. On the evolution of some endoscopic light delivery systems for photodynamic therapy. Endoscopy 30 4 (1998) 392-407
90. Panjehpour M., Overholt B.F., and Haydek J.M. Light sources and delivery devices for photodynamic therapy in the gastrointestinal tract. Gastrointest Endosc Clin N Am 10 3 (2000) 513-532
91. Overholt B.F., Panjehpour M., DeNovo R.C., et al. Balloon photodynamic therapy of esophageal cancer: effect of increasing balloon size. Lasers Surg Med 18 3 (1996) 248-252
92. Prasad G.A., Wang K.K., Buttar N.S., et al. Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc 65 1 (2007) 60-66
93. Stepinac T., Grosjean P., Woodtli A., et al. Optimization of the diameter of a radial irradiation device for photodynamic therapy in the esophagus. Endoscopy 34 5 (2002) 411-415
94. Braichotte D.R., Savary J.F., Monnier P., et al. Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy. Lasers Surg Med 19 3 (1996) 340-346
95. Zellweger M., Grosjean P., Monnier P., et al. Stability of the fluorescence measurement of Foscan in the normal human oral cavity as an indicator of its content in early cancers of the esophagus and the bronchi. Photochem Photobiol 69 5 (1999) 605-610
96. Standish B.A., Yang V.X., Munce N.R., et al. Doppler optical coherence tomography monitoring of microvascular tissue response during photodynamic therapy in an animal model of Barrett's esophagus. Gastrointest Endosc 66 2 (2007) 326-333
97. Wong D.J., Paulson T.G., Prevo L.J., et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 61 22 (2001) 8284-8289
98. Prevo L.J., Sanchez C.A., Galipeau P.C., et al. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 59 19 (1999) 4784-4787
99. Prasad G.A., Wang K.K., Halling K.C., et al. Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer 113 3 (2008) 470-476
100. Hornick J.L., Mino-Kenudson M., Lauwers G.Y., et al. Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities. Am J Gastroenterol 103 1 (2008) 38-47
101. Panjehpour M., Coppola D., Overholt B.F., et al. Photodynamic therapy of Barrett's esophagus: ablation of Barrett's mucosa and reduction in p53 protein expression after treatment. Anticancer Res 28 1B (2008) 485-489
102. Ginsberg G.G., Furth E.E., Ginsberg J., et al. Multi-modal endoluminal eradication therapy for specialized intestinal metaplasia of the esophagus and the esophagogastric junction with high-grade dysplasia and/or intramucosal carcinoma. Gastrointest Endosc Clin N Am 65 5 (2007) AB154
103. Shaheen N.J., Sharma P., Overholt B.F., et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 360 22 (2009) 2277-2288
104. Kahaleh M., Van Laethem J.L., Nagy N., et al. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. Endoscopy 34 12 (2002) 950-955
105. Shaheen N.J., Inadomi J.M., Overholt B.F., et al. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut 53 12 (2004) 1736-1744
106. Tan W.C., Fulljames C., Stone N., et al. Photodynamic therapy using 5-aminolaevulinic acid for oesophageal adenocarcinoma associated with Barrett's metaplasia. J Photochem Photobiol B 53 1-3 (1999) 75-80
107. Mackenzie G.D., Jamieson N.F., Novelli M.R., et al. How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett's esophagus. Lasers Med Sci 23 2 (2008) 203-210
108. Ackroyd R., Kelty C.J., Brown N.J., et al. Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up. Endoscopy 35 6 (2003) 496-501